Autologous cell therapies: challenges in US FDA regulation
Read this Opinion, published in Regenerative Medicine, to understand why after 30 years of laboratory and clinical efforts fueled by countless billions in public and private funding, cell-based therapies have not made a greater impact.
Please sign in or register for FREE
Sign in to RegMedNet
Register to RegMedNet
RegMedNet is a free content and networking hub promoting global connection, knowledge-sharing and collaboration between all members of the regenerative medicine field.